Drugs / MDI-1228
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05969236 | Oct 2023 → Apr 2024 | conjunctivitis | Shanghai Medinno Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06852976 | Mar → Dec 2025 overdue | ulcer of lower limbs | Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDI-1228 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05969236 ↗ |
| Route | Other | “by Local Instillation” NCT05969236 ↗ |